Discussion Resmetirom was approved by the FDA as the first and thus far only MASH therapeutic drug, and the GLP-1 analog semaglutide showed positive effects in patients with MASH in a phase III clinical trial 35
How Your Genetics Relate to GLP-1 Pathways The PlexusDx Precision Peptide Genetic Test analyzes FTO and MC4R variants that relate to GLP-1 and related signaling pathways
The test identifies these predispositions, allowing PlexusDx to recommend targeted supplementation that addresses your individual metabolic signature
The relative small number of patients that underwent double OGTT (n = 51) may also be a limitation
Better health, self-confidence, appearance, and professional life are all great reasons, and while the motivation is there, that isnt always enough to reach weight loss goals
1, mechanistically, skin is exposed to oxidants or ROS from the environment that induce tremendous oxidation reactions leading to skin damage and aging [150]